Retinopathy News and Research

RSS

New results from ADVANCE provide important insights to reduce diabetes complications

New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, provide important insights into the therapeutic strategy to adopt for efficient and safe blood glucose control aimed at the reduction of severe diabetes complications.

21 Oct 2009

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species -- mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103.

14 Oct 2009

Increasing number of pre-term infants experience eye disorders

As more extremely pre-term infants survive in Sweden, an increasing number of babies are experiencing vision problems caused by abnormalities involving the retina, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

13 Oct 2009

Common myths about children's eye health and the medical reality behind them

Many parents grew up with medical adages or advice that have since been proven by scientists to be incorrect or outdated. Here are five common myths about children's eye health and the medical reality behind them, prepared by the physicians at The Vision Center at Childrens Hospital Los Angeles.

12 Oct 2009

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease, vascular disease and cancer, today announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME).

6 Oct 2009

Study finds that visual impairment in T1D patients may be decreasing

People diagnosed with type 1 diabetes (T1D) in recent years are less likely to develop diabetes-related vision loss than those diagnosed in earlier years, says a new study funded by the National Eye Institute, a division of the National Institutes of Health. Forecasts of visual impairment prevalence in T1D patients may need to be amended, the researchers suggest, since current predictions assume that the earlier incidence rates will continue.

3 Oct 2009

ThromboGenics completes enrollment for MIVI-TRUST clinical trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the US Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

24 Sep 2009

New device for identifying eye conditions in infants

Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.

22 Sep 2009

Sight for Life Foundation offers free vision care

The CIGNA (NYSE:CI) Foundation today named Dr. Eva Liang, an ophthalmologist with the Cigna Medical Group in Phoenix, as the company’s Volunteer of the Year. Dr. Liang founded the Sight for Life Foundation in 2001 while in private practice in Las Vegas.

19 Sep 2009

New technique found that may prevent vision loss

Blocking a protein that battles infection may help thwart a common cause of vision loss in chronic diseases such as diabetes, Medical College of Georgia researchers say.

16 Sep 2009

Stemedica files patent application for diabetic retinopathy treatment

Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, has filed a patent application with the United States Patent and Trademark Office ("USPTO") for a proprietary methodology in the treatment for Diabetic Retinopathy.

8 Sep 2009

$NEI awards grant to Vivakor for developing a digital photo-refractor$

NEI awards grant to Vivakor for developing a digital photo-refractor

Vivakor, Inc. announced that the National Institutes of Health-National Eye Institute has awarded a grant to Vivakor, Inc. in Coralville, IA through the Small Business Innovation Research Awards.

4 Sep 2009

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

Masimo SET pulse oximetry technology implemented in Childrens Hospital Los Angeles

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Childrens Hospital Los Angeles, ranked by U.S. News & World Report as one of 'America's Best Children's Hospitals', has completed its system-wide conversion to Masimo SET pulse oximetry technology.

26 Aug 2009

Researchers find connection between eye disease and arginase

Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy.

19 Aug 2009

Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases

A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier.

3 Aug 2009

Stopping type 1 diabetes damage with vitamin C

Researchers at the Harold Hamm Oklahoma Diabetes Center have found a way to stop the damage caused by Type 1 diabetes with the combination of insulin and a common vitamin found in most medicine cabinets.

9 Jun 2009

Diabetics who have retinopathy should also be screened for obstructive sleep apnea

The eyes may be the window into the soul, but they may also contain important medical information. According to new research to be presented at the American Thoracic Society's 105th International Conference in San Diego on May 19, patients with diabetes who have retinopathy should also be screened for obstructive sleep apnea (OSA).

19 May 2009

Protein kinase JNK1 identified as treatment target for retinopathy in premature babies

Results of a study in mice by researchers at the University of California, San Diego strongly suggest that the protein kinase JNK1 plays a key role in the development of retinopathy in premature infants.

4 May 2009